Brief: Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In COVID-19
29/12/2021 21:52
Dec 29 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON PHASE 3 CLINICAL
TRIAL
FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS LTD - NO SERIOUS ADVERSE EVENTS AND
SAFETY
CONCERNS REPORTED TO DATE IN PHASE 3 CLINICAL TRIAL
* REVIVE THERAPEUTICS LTD - EXPECTED TO COMPLETE ENROLLMENT
IN
Q1-2022
* REVIVE THERAPEUTICS LTD - TO DATE, STUDY HAS SCREENED
APPROXIMATELY 700 SUBJECTS
* REVIVE THERAPEUTICS LTD - NOT MAKING ANY EXPRESS OR
IMPLIED
CLAIMS THAT ITS PRODUCT HAS ABILITY TO ELIMINATE OR CURE
COVID-19 AT THIS TIME
Source text for Eikon: ID:nGNXc10sNk
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure